Granulocyte transfusions have been advocated by some for the treatment of severe, progressive infections in neutropenic patients who fail to respond to antimicrobial agents and recombinant hematopoietic growth factors. We conducted the current study to determine an appropriate method of granulocyte mobilization in healthy donors, and to evaluate the safety and efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. To mobilize granulocytes (n = 55), healthy normal donors were stimulated in one of the following ways: (1) dexamethasone, 3 mg/m 2 intravenously 15 min prior to leukapheresis (n = 5); (2) granulocyte colony-stimulating factor (G-CSF), 5 g/kg subcutaneously 12 to 14 h prior to collection (n = 37); or (3) G-CSF and dexamethasone (n = 13). The mean granulocyte yield from stimulation with G-CSF plus dexamethasone was significantly higher than from stimulation with dexamethasone or G-CSF alone. Twenty-five patients with severe neutropenia-related infections unresponsive to appropriate antimicrobial agents received a total of 55 granulocyte transfusions. The patients from whom fungi or Gram-negative organisms were isolated showed a more favorable response than those infected with Gram-positive organisms. However, the responses to the granulocyte transfusion therapy could not be correlated with the transfused dose, mobilization agents, or the 1 h or 24 h post-transfusion absolute neutrophil counts. We conclude that granulocyte transfusion therapy may be clinically useful for neutropenia-related infections by fungi or Gram-negative organisms. Leukemia (2001) 15, 203-207. 
Introduction
Neutropenia-related infection is a major factor contributing to morbidity and mortality in patients with hematologic malignancy despite appropriate antibiotic therapy. [1] [2] [3] Although the use of hematopoietic growth factor such as granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces the duration of neutropenia, bacterial or fungal infections in these patients still contribute to mortality. 4, 5 Granulocyte transfusion therapy was enthusiastically advocated in the 1970s and early 1980s. [5] [6] [7] [8] [9] [10] However, the use of granulocyte transfusion therapy has rapidly declined, due in part to toxicity and the introduction of new antimicrobial agents and recombinant hematopoietic growth factors. [5] [6] [7] [8] [9] [10] Recently, granulocyte transfusion therapy has received renewed interest following several reports of efficacy following transfusion of granulocytes collected from normal donors stimulated with G-CSF. [9] [10] [11] [12] [13] [14] Mobilizing agents used to stimulate granulocytosis in healthy donors include corticosteroids and G-CSF. Administration of G-CSF results in a significantly higher granulocyte dose per collection than that of corticosteroids. 10, 11, 15, 16 Recently, some investigators reported that approximately 10 times as many granulocytes could be collected using corticosteroid and G-CSF in combination, without increased toxicity. 10, [17] [18] [19] However, direct comparisons of these mobilizing agents in the clinical setting are limited, and the best mobilizing regimen remains to be established.
We therefore conducted the current study to determine the best method of mobilizing granulocytes in healthy donors, and to evaluate the safety and efficacy of granulocyte transfusion therapy in patients with severe neutropenia-related infections.
Materials and methods

Donors
All donors were ABO-compatible with the recipients, and were screened and accepted according to the American Association of Blood Bank guidelines. Most of the donors volunteered for platelet apheresis and a few donors were members of the patient's family. After obtaining informed consent, healthy donors were given one of the following regimens: (1) dexamethasone, 3 mg/m 2 given intravenously 15 min before collection; (2) G-CSF, single dose of 5 g/kg subcutaneously 12 to 14 h before collection; (3) G-CSF, 5 g/kg subcutaneously 12 to 14 h before collection, plus dexamethasone, 3 mg/m 2 given intravenously 15 min before collection. Blood samples were obtained from the donors by venipuncture before the administration of each mobilizing agent, before leukapheresis, and after leukapheresis to determine the white cell counts (WBCs) and absolute neutrophil counts (ANCs).
Granulocyte collections
All granulocyte concentrates were collected with a Fenwall CS 3000 Plus blood cell separator using 500 to 1000 ml of 10% low molecular weight starch (Pentaspan; Du Pont Critical Care, Waukegan, IL, USA) per procedure, plus 15 to 30 ml of 46.7% citrate concentrate (A.C.D-A solution; Green Cross Medicals Co., Yongin, Korea). Starch-citrate was infused at 1 ml per liter of donor blood volume per min, in a 1:13 starch-citrate/WBC ratio with whole blood. Six to 10 liters of blood were processed for each procedure.
Granulocyte transfusion
Each leukapheresis product (200 ml) was irradiated with 25 Gy before infusion. After premedicating the patients with acetaminophen, pheniramine maleate and hydrocortisone, the granulocytes were infused over 60 to 90 min. Patients receiving amphotericin B received the granulocyte after an interval of at least 4 to 6 h. Blood samples from patients were obtained by venipuncture at baseline and 1 h and 24 h after the granulocyte transfusions.
Granulocyte transfusions were given at least daily until: (1) the blood granulocyte level in the recipient had increased to Ͼ500/l; (2) the infection cleared; (3) no more donors were available; or (4) a severe transfusion reaction developed.
Patients
Patients with neutropenia (ANC Ͻ500/l) and severe, progressive infections that could not be controlled, despite the use of appropriate antibacterial or fungal agents, G-or GM-CSF, or IVIG were eligible for inclusion. All patients gave informed consent. Patients who did not show a response to platelet transfusion were excluded from the study to avoid complications due to alloimmunization. Twenty-five patients received granulocyte infusions and the patients' characteristics are summarized in Table 1 .
Response evaluation and statistical analysis
The response to the granulocyte transfusion was considered to be 'favorable' if the clinical symptoms and signs of infection, including radiological findings, decreased, and cultures from the previously infected site were negative, or 'unfavorable' if the clinical symptoms and signs of infection were unchanged or worse.
All statistical analyses were performed with the program SPSS 10.0. ANCs in donors for the different mobilizing agents and clinical responses and variables for granulocyte transfusions were compared using the Mann-Whitney U test, Kruskal Wallis test, or 2 test. P values Ͻ0.05 were considered statistically significant. 
Results
Donors
Of 55 granulocyte collections, five (9.1%) donors were given dexamethasone alone before leukapheresis, 37 (67.3%) were given G-CSF alone, and 13 (23.6%) were given G-CSF plus dexamethasone. The mobilizing agents were well tolerated, except for mild bone pain or myalgia. Whereas dexamethasone induced a modest increase in the mean ANC from 2803/l at baseline to 2996/l before collection, G-CSF or G-CSF plus dexamethasone induced a severalfold increase in the mean ANC from 4714/l or 5410/l at baseline to 18 915/l or 22 383/l before collection (P Ͻ 0.009), respectively. The mean ANC after leukapheresis was 4078/l for dexamethasone, 11 232/l for G-CSF and 18 588/l for G-CSF plus dexamethasone (P = 0.001). The mean granulocyte yield from the administration of mobilizing agents was 5.1 × 10 10 (range, 1.8-11.1) for dexamethasone, 5.5 × 10 10 (range, 0.2-19.6) for G-CSF and 10.6 × 10 10 (range, 4.7-17.9) for G-CSF plus dexamethasone (P = 0.01) ( Table 2) .
Patients
There were 20 males (80%) and five females (20%). The median age of the patients was 38 years (range, 7-62). The patient's diagnoses included acute myeloid leukemia (n = 16), non-Hodgkin's lymphoma (n = 2), acute lymphoid leukemia (n = 1), chronic myeloid leukemia (n = 1), chronic lymphoid leukemia (n = 1), aplastic anemia (n = 1), myelodysplastic syndrome (n = 1), multiple myeloma (n = 1) and primitive neuroectodermal tumor (n = 1). The median duration of neutropenia before granulocyte transfusion was 13 days (range, 5-30), and the median durations of the therapy with antimicrobial agents and G-CSF/GM-CSF before granulocyte transfusion were 11 days (range, 5-26) and 9 days (range, 5-26), respectively. Most patients were classified as score 3 (n = 5, 20%) or 4 (n = 20, 80%) on the ECOG performance scale. Infection sites and organisms isolated from the patients are presented in Table 3 .
Granulocyte transfusions
Patients received a mean of 2.1 granulocyte transfusions (range, 1-7) and a mean dose of 6.6 × 10 10 granulocytes (range, 0.2-19.6 × 10 10 ). Ten patients (40%) had favorable responses whereas 15 patients (60%) had unfavorable responses (Table 3) . Favorable responses were seen more often in patients from whom fungal or Gram-negative organisms were isolated than those infected with Gram-positive organisms (72.7%, P = 0.005; 60%, P = 0.018, vs 31.3%, P = 0.234). The 1 h and 24 h post-transfusion ANCs of patients with a favorable response were not significantly higher than those of patients with an unfavorable response (means 557/l and 419/l vs 289/l and 342/l, respectively, P = 0.110 and P = 0.604). In addition, the transfused dose and the mobilizing agent did not influence the response to granulocyte transfusion therapy (Table 4) .
Most of the granulocyte transfusions were well tolerated. However, adverse reactions to granulocyte transfusion were seen; pulmonary edema occurred in two patients (8%), transient hypoxia in one patient (4%), and paroxysmal supraventricular tachycardia in one patient (4%). Unfortunately, one patient with pulmonary edema died from a severe pulmonary reaction. In addition, there were 12 deaths in these events, resulting from 205 Table 2 Absolute neutrophil count (ANC) changes and granulocyte yield with the three mobilizing agents infections in eight patients, aggravations of underlying diseases in four patients, or unexpectively intracerebral hemorrhage after improvement of infection in one patient. Finally, eight (53%) of 15 patients with unfavorable response for granulocyte transfusion succumbed to infection ( Table 2) .
Discussion
While still controversial, our study suggests that granulocyte transfusions are an effective adjuvant therapy for neutropeniarelated infection refractory to antimicrobial agents, and that refractory infections with fungi or Gram-negative organisms are major independent response factors for granulocyte transfusion therapy. In this study, patients from whom fungi were isolated showed a 72% favorable response rate; this result is similar to recent reports from other investigators. 12,17 When G-CSF plus dexamethasone was used to mobilize granulocytes in healthy donors, the granulocyte yield was greater than with G-CSF or dexamethasone alone. However, the mobilizing agent or granulocyte dose did not significantly influence the clinical response. This might have occurred simply because most of the granulocyte yields collected in the study were sufficient to treat the neutropenia-related infection (over 80% of doses at least 2 × 10 10 ). Neutropenia-related infections in cancer patients are not only one of the major factors contributing to morbidity and mortality despite the use of broad-spectrum antibacterial or antifungal agents, but are also the most important factor limiting treatment with intensive chemotherapy. [1] [2] [3] More than 20 years ago, granulocyte transfusion therapy was widely used clinically with the popularization of intermittent flow centrifugation devices. The use of this therapy declined dramatically for several reasons, including difficulties in storing and processing granulocytes, the development of more potent antimicrobial agents and alternative agents such as recombinant hematopoietic growth factors and IVIG, and the lack of randomized trials demonstrating efficacy. [5] [6] [7] [8] [9] [10] In the early 1990s, Bensinger et al 11 demonstrated that high yields of granulocytes could be collected safely from normal donors by administering G-CSF, and Strauss 6 suggested that the major factor limiting the clinical efficacy of granulocyte therapy might be the relatively small dose of granulocytes achievable with conventional mobilizing strategies. Subsequently, renewed enthusiasm followed several reports of clinical efficacy in patients receiving larger doses of granulocytes. [11] [12] [13] [14] [20] [21] [22] Granulocyte therapy is given mainly to patients who have severe, progressive infection with neutropenia that fails to respond to appropriate antimicrobial agents within approximately 48 h.
6,7
Leukemia
The minimum cell dose required for a measurable neutrophil increment is 2 to 3 × 10 10 . 6, 7 Transfusions are often continued until the ANC has increased above 500/l and the infection has resolved. 6, 7 Prophylactic use of granulocyte transfusion is not recommended because of its unproven clinical effectiveness and the risks of alloimmunization and cytomegalovirus transmission. 23, 24 Maximum granulocyte yields of up to 2 to 3 × 10 10 can be obtained from donors stimulated with corticosteroids. 10 In contrast, G-CSF-stimulated, daily or every other day administration, donors routinely yield 4 × 10 10 or more functionally normal granulocytes. 10, 11, 15, 16 Recently, some investigators have combined G-CSF and corticosteroids to increase the yield of granulocytes and reported an average yield of 8.3 × 10 10 granulocytes. 10, [17] [18] [19] These findings were confirmed in our study, with mean granulocyte yields of 5.1 × 10 10 for G-CSF and 10.6 × 10 10 for G-CSF plus dexamethasone. The granulocyte yields with dexamethasone stimulation alone are not considered because of the limited number of collections.
Our study suggests that patients with refractory fungal and Gram-negative infections may benefit from granulocyte transfusion therapy, while no such effect in patients with infections with Gram-positive organisms could be demonstrated; however, the reason for this difference is not clear. Preliminary results 25 of our ongoing study using granulocyte scintigraphy with 99m Tc-HMPAO in patients with neutropenia-related infections showed that sites of fungal and Gram-negative infection show abnormal early uptake and persistent retention, while uptake is normal at sites of Gram-positive infection. These findings suggest that it may be possible to use granulocyte scintigraphy to predict the response to granulocyte transfusion therapy.
During or after granulocyte transfusions, recipients can develop transfusion reactions with fever or chills, and are at risk of cytomegalovirus infection. 7, 9 In alloimmunized recipients, these adverse reactions can be associated with severe pulmonary reactions including dyspnea, pulmonary edema, and respiratory failure. 7, 9, 17, 26, 27 Severe adverse reactions were also seen in our study, with pulmonary edema in two patients and tachyarrhythmia in one patient. 28 Early detection of these adverse reactions requires ECG and pulse oxymetry monitoring during granulocyte transfusion therapy in patients with neutropenia-related infection.
This study demonstrates that granulocyte transfusion is an effective adjuvant therapeutic method in patients with neutropenia and fungal or Gram-negative infections resistant to appropriate antimicrobial agents. Further clinical and laboratory studies are needed to further define patients most likely to benefit from granulocyte transfusion therapy. 
